Announced details
Treatment of intractable diseases, primarily kidney disease; regenerative medicine; drug discovery
Toho Holdings invested in リジェネフロ株式会社. The companies will cooperate in research and development and distribution.
Based in Kyoto Prefecture. Its representative director and CEO is Morinaka Akifumi (森中紹文). It is a clinical-stage drug discovery startup based on research conducted by Professor Osafune Kenji (長船健二) of the Center for iPS Cell Research and Application at Kyoto University. The company conducts research and development, production and sales of drugs for kidney disease. Established on 20 September 2019, it has capital of ¥2,276,093,400, including capital reserves. Its address is 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto, Kyoto University Medical Science and Pharmaceutical Research Building.
〒606-8501 Kyoto University Medical Science and Pharmaceutical Research Building, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto
The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | RN‐014, Drugs for kidney disease, Regenerative medicine products |
| Counterparty | リジェネフロ株式会社 |
| Counterparty overview | Based in Kyoto Prefecture. Its representative director and CEO is Morinaka Akifumi (森中紹文). It is a clinical-stage drug discovery startup based on research conducted by Professor Osafune Kenji (長船健二) of the Center for iPS Cell Research and Application at Kyoto University. The company conducts research and development, production and sales of drugs for kidney disease. Established on 20 September 2019, it has capital of ¥2,276,093,400, including capital reserves. Its address is 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto, Kyoto University Medical Science and Pharmaceutical Research Building. |
| Relationship with the Company | Toho Holdings invested in リジェネフロ株式会社. The companies will cooperate in research and development and distribution. |
| Applicable area | Treatment of intractable diseases, primarily kidney disease; regenerative medicine; drug discovery |
| Location | 〒606-8501 Kyoto University Medical Science and Pharmaceutical Research Building, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto |
| Impact on Business Performance | The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To support リジェネフロ株式会社’s research and development, deepen knowledge of regenerative medicine products and other products expected to achieve future growth, and cooperate in distribution so that patients with intractable diseases can receive innovative treatments.